Search JIM Advanced Search

Journal of Chinese Integrative Medicine ›› 2008, Vol. 6 ›› Issue (2): 166-170.doi: 10.3736/jcim20080212

• Original Experimental Research • Previous Articles     Next Articles

Immunomodulatory effects of Astragalus polysaccharide in diabetic mice

Ru-jiang Li1, Shu-dong Qiu1(), Hong-xia Chen2, Li-rong Wang1   

  1. 1. Reproduction Centre, Medical School, Xian Jiao Tong University, Xian, Shannxi Province 710061, China
    2. Institute of Pharmacology and Toxicology, Academy of Military Medical Sciences, Beijing 100850, China
  • Received:2007-04-17 Online:2008-02-20 Published:2008-02-15
  • Contact: QIU Shu-dong

Objective:To study the immunomodulatory effects of Astragalus polysaccharide (APS) in type 1 diabetic mice.

Methods:A mouse model of type 1 diabetes mellitus was established by intraperitoneal injection of multiple low dose streptozotocin (MLD-STZ). The diabetic mice were intraperitoneally administered 100, 200, 400 mg/kg APS or 1 ml normal saline (NS) every day respectively, then the diabetic mice were sacrificed after 15 or 30 days of treatment. The effect of APS on insulitis was determined via pancreatic histological analysis. Serum insulin autoantibody (IAA) levels were measured by radio-immunoassay (RIA). Proliferation ability of splenocytes to concanavalin A was tested by using [ 3H] thymidine incorporation assay. The levels of cytokine interferon-γ (IFN-γ) and interleukin-4 (IL-4) secreted by splenocytes were determined by enzyme linked immunosorbent assay (ELISA) method, and the expression of peroxisome proliferator-activated receptor gamma (PPARγ) in spleens was characterized using Western-blot analysis.

Results:Attenuated insulitis, down-regulation of the serum IAA levels and Th1/Th2 cytokine ratio, decrease of the proliferation ability of splenocytes to concanavalin A, and up-regulation of the PPARγ levels in spleens showed a significant time- and dose-dependent response to APS treatment as compared with the NS-treated group.

Conclusion:APS possesses immunotherapeutic effects on mice with type 1 diabetes mellitus through improving the cell- and humoral-mediated immunity.

Key words: Astragalus, diabetes mellitus, typel, immunomodulators, mice

CLC Number: 

  • R587.1

Table 1

Effect of APS on IAA in diabetic mice after 15 or 30 days of treatment ($\bar{x}$±s)"

Group n IAA level at day 15 IAA level at day 30
Normal control 10 1 207.7±99.6 1 238.5±118.1
NS-treated 10 1 798.7±98.2** 1 813.2±101.9**
Low-dose APS-treated 10 1 718.1±149.9** 1 559.5±112.1△△**
Medium-dose APS-treated 10 1 682.6±94.7** 1 485.8±119.3△△**
High-dose APS-treated 10 1 679.8±156.1** 1 355.7±131.0△△*

Figure 1

Pancreata immuno-labled for insulin and counterstained for lymphocytic infiltration in pancreas islets after 30 days of APS treatment (DAB staining and hematoxylin counterstaining, ×200) A: Normal control group; B: Untreated group; C: Low-dose APS-treated group; D: Medium-dose APS-treated group; E: High-dose APS-treated group."

Table 2

Proliferation ability of splenocytes treated with Con A after 15 or 30 days of administration of APS ($\bar{x}$±s)"

Group n CPM at day 15 CPM at day 30
Normal control 5 9 427.5±1 613.6 8 936.4±2 036.4
NS-treated 5 15 950.1±2 262.2** 19 729.6±2 345.8**
Low-dose APS-treated 5 14 410.0±2 781.8** 13 417.2±2 919.1**
Medium-dose APS-treated 5 14 111.4±2 327.3** 12 994.5±2 849.4**
High-dose APS-treated 5 13 999.8±2 636.9** 12 008.1±2 970.4**

Table 3

Effect of APS on productions of IL-4, IFN-γ and IFN-γ/IL-4 ratio of diabetic splenocytes induced by Con A ($\bar{x}$±s)"

Group n 15 days of treatment 30 days of treatment
IL-4 (ng/L) IFN-γ (ng/L) IFN-γ/IL-4 IL-4 (ng/L) IFN-γ (ng/L) IFN-γ/IL-4
Normal control 5 241±6 227±18 0.94±0.06 238±21 243±20 1.02±0.06
NS-treated 5 181±52** 303±45** 1.71±0.11** 156±37** 308±37** 2.05±0.45**
Low-dose APS-treated 5 189±31* 281±44** 1.90±0.09** 167±31** 277±41 1.71±0.33**
Medium-dose APS-treated 5 191±41* 284±38** 1.52±0.08** 205±52 265±38 1.34±0.29△△
High-dose APS-treated 5 192±31* 285±51** 1.49±0.09** 222±45△△ 255±29△△ 1.17±0.14△△

Figure 2

Western blot analysis of PPARγ protein expression in spleens of diabetic mice after 30 days of APS treatment1: Normal control group; 2: Untreated group; 3: Low-dose APS-treated group; 4: Medium-dose APS-treated group; 5: High-dose APS-treated group."

[1] Roep BO . The role of T-cells in the pathogenesis of type 1 diabetes: from cause to cure. Diabetologia. 2003; 46(3):305-321.
doi: 10.1007/s00125-003-1089-5 pmid: 12687328
[2] Silveira PA, Grey ST . B cells in the spotlight: innocent bystanders or major players in the pathogenesis of type 1 diabetes. Trends Endocrinol Me tab. 2006; 17(4):128-135.
doi: 10.1016/j.tem.2006.03.006
[3] Lipsett M, Aikin R, Hanley S , et al. Islet neogenesis: a potential therapeutic tool in type 1 diabetes. Int J Biochem Cell Biol. 2006; 38(4):498-503.
doi: 10.1016/j.biocel.2006.02.005 pmid: 16607698
[4] Su L, Mao JC , Gu JH. Effect of intravenous drip infusion of cyclophosphamide with high-dose Astragalus injection in treating lupus nephritis. Zhong Xi Yi Jie He Xue Bao. 2007; 5(3):272-275. Chinese with abstract in English.
苏励, 茅建春, 顾军花 . 环磷酰胺联合大剂量黄芪注射液静脉滴注治疗狼疮性肾炎.中西医结合学报. 2007; 5(3):272-275.
[5] Chen W, Liu F, Yu MH , et al. Astragalus polysaccharide prevent type 1 diabetes in nonobese diabetic mice. Fu Dan Xue Bao ( Yi Xue Ke Xue Ban). 2001; 28(1):57-60. Chinese with abstract in English.
doi: 10.3969/j.issn.1672-8467.2001.01.016
陈蔚, 刘芳, 俞茂华 , 等. 黄芪多糖对NOD小鼠1型糖尿病的预防作用. 复旦学报(医学科学版). 2001; 28(1):57-60.
doi: 10.3969/j.issn.1672-8467.2001.01.016
[6] Weng L, Liu Y, Liu XY , et al. Effect of Astragalus polysaccharide on splenocyte cytokine secretion patterns and NK cells. Zhong Yi Yao Xue Kan. 2003; 21(9):1522-1524. Chinese.
翁玲, 刘彦, 刘学英 , 等. 黄芪多糖粉针剂对小鼠脾细胞分泌细胞因子及NK杀伤能力的影响.中医药学刊. 2003; 21(9):1522-1524.
[7] Gor DO, Rose NR, Greenspan NS . TH1-TH2: a Procrustean paradigm. Nat Immunol. 2003; 4(6):503-505.
doi: 10.1016/j.envpol.2008.09.038 pmid: 12774069
[1] Mohadeseh Ostovar, Abolfazl Akbari, Mohammad Hossein Anbardar, Aida Iraji, Mohsen Salmanpour, Salar Hafez Ghoran, Mojtaba Heydari, Mesbah Shams. Effects of Citrullus colocynthis L. in a rat model of diabetic neuropathy. Journal of Integrative Medicine, 2020, 18(1): 59-67.
[2] Olakunle Bamikole Afolabi, Omotade Ibidun Oloyede, Shadrack Oludare Agunbiade. Inhibitory potentials of phenolic-rich extracts from Bridelia ferruginea on two key carbohydrate-metabolizing enzymes and Fe2+-induced pancreatic oxidative stress. Journal of Integrative Medicine, 2018, 16(3): 192-198.
[3] Chun-song Hu, Tengiz Tkebuchava. SEEDi1.0-3.0 strategies for major noncommunicable diseases in China. Journal of Integrative Medicine, 2017, 15(4): 265-269.
[4] Uduak Akpan Okon, Idorenyin Udo Umoren. Comparison of antioxidant activity of insulin, Ocimum gratissimum L., and Vernonia amygdalina L. in type 1 diabetic rat model. Journal of Integrative Medicine, 2017, 15(4): 302-309.
[5] Nazli Samadi, Hassan Mozaffari-Khosravi, Masoud Rahmanian, Mohsen Askarishahi. Effects of bee propolis supplementation on glycemic control, lipid profile and insulin resistance indices in patients with type 2 diabetes: A randomized, double-blind clinical trial. Journal of Integrative Medicine, 2017, 15(2): 124-134.
[6] Yee Chi Peggy Wong. Need of integrated dietary therapy for persons with diabetes mellitus and “unhealthy” body constitution presentations. Journal of Integrative Medicine, 2016, 14(4): 255-268.
[7] Ausanee Wanchai, Duangjai Phrompayak. Use of complementary and alternative medicine among Thai patients with type 2 diabetes mellitus. Journal of Integrative Medicine, 2016, 14(4): 297-305.
[8] Sulaiman Al-Eidi, SalwaTayel, Fatima Al-Slail, Naseem Akhtar Qureshi, Imen Sohaibani, Mohamed Khalil, Abdullah Mohammad Al-Bedah. Knowledge, attitude and practice of patients with type 2 diabetes mellitus towards complementary and alternative medicine. Journal of Integrative Medicine, 2016, 14(3): 187-196.
[9] Mohammad Hashem Hashempur, Mojtaba Heydari, Seyed Hamdollah Mosavat, Seyyed Taghi Heydari, Mesbah Shams. Complementary and alternative medicine use in Iranian patients with diabetes mellitus. Journal of Integrative Medicine, 2015, 13(5): 319-325.
[10] Ahmad Ghorbani. Clinical and experimental studies on polyherbal formulations for diabetes: Current status and future prospective. Journal of Integrative Medicine, 2014, 12(4): 336-345.
[11] Qian Zhang, Xin-hua Xiao, Ming Li, Wen-hui Li, Miao Yu, Hua-bing Zhang, Fan Ping, Zhi-xin Wang, Jia Zheng ​. Chromium-containing traditional Chinese medicine, Tianmai Xiaoke Tablet improves blood glucose through activating insulin-signaling pathway and inhibiting PTP1B and PCK2 in diabetic rats. Journal of Integrative Medicine, 2014, 12(3): 162-170.
[12] Rajadurai Akilen​, Zeller Pimlott​, Amalia Tsiami​, Nicola Robinson​. The use of complementary and alternative medicine by individuals with features of metabolic syndrome. Journal of Integrative Medicine, 2014, 12(3): 171-174.
[13] Hai-li Jiang, Jing-jing Ni, Wei-fei Zhang, Wen-jin Huang​, Ming-yue Zhou​, Wen-jun Sha​, Jun-yan Li​, Fu-feng Li​, Zhu Ting​​, Xin Xia, Jun Zhang​, Yuan-dong Shen​, Li-gang Zhou​. The role of central nervous system on hypoglycemia and the feasibility of the brain theory in traditional Chinese medicine on treatment of diabetes mellitus. Journal of Integrative Medicine, 2014, 12(1): 1-6.
[14] Dilpesh Jain​, Manish Kumar Bansal, Rahul Dalvi​, Aman Upganlawar​, Rahul Somani​. Protective effect of diosmin against diabetic neuropathy in experimental rats. Journal of Integrative Medicine, 2014, 12(1): 35-41.
[15] Abdullah Bamosa. Nigella sativa is a safe herbal product. Journal of Integrative Medicine, 2014, 12(1): 66-66.
Full text



[1] Jun Hu, Jian-ping Liu. Non-invasive physical treatments for chronic/recurrent headache. Journal of Chinese Integrative Medicine, 2008, 6(1): 31
[2] Hai-feng Wei, Bai-liu Ya, Ling Zhao, Cui-fei Ye, Li Zhang, Lin Li. Evaluation of tongue manifestation of blood stasis syndrome and its relationship with blood rheological disorder in a rat model of transient brain ischemia. Journal of Chinese Integrative Medicine, 2008, 6(1): 73-76
[3] Xi Lin, Jian-ping Liu. Herbal medicines for viral myocarditis. Journal of Chinese Integrative Medicine, 2008, 6(1): 76
[4] Xin-jun Wang, Ling-ling Wang . A mechanism of endogenous opioid peptides for rapid onset of acupuncture effect in treatment of depression. Journal of Chinese Integrative Medicine, 2010, 8(11): 1014-1017
[5] Jing-yuan Mao, Chang-xiao Liu, Heng-he Wang, Guang-li Wei , Zhen-peng Zhang, Jie Xing, Wang Xian liang , Ying-fei Bi . Effects of Shenmai Injection on serum concentration and pharmacokinetics of digoxin in dogs with heart failure. Journal of Chinese Integrative Medicine, 2010, 8(11): 1070-1074
[6] Chan Chen, Yong-mei Meng , Peng Zhang, Juan Wang, Hui-hui Zhao, Shu-zhen Guo , Wei Wang. Diagnosis and treatment rule of traditional Chinese medicine for syndrome factors of chronic congestive heart failure: a study based on Shannon entropy method. Journal of Chinese Integrative Medicine, 2010, 8(11): 1080-1084
[7] Pedro Saganha João, Doenitz Christoph, Greten Tobias, Efferth Thomas, J. Greten Henry. Qigong therapy for physiotherapists suffering from burnout: a preliminary study. Journal of Chinese Integrative Medicine, 2012, 10(11): 1233-1239
[8] Ming-qing Wei , Jin-zhou Tian , Jing Shi , Fu-yun Ma , Ying-chun Miao , Yong-yan Wang. Effects of Chinese medicine for promoting blood circulation and removing blood stasis in treating patients with mild to moderate vascular dementia: a randomized, double-blind and parallel-controlled trial. Journal of Chinese Integrative Medicine, 2012, 10(11): 1240-1246
[9] Ying Xu , Chang-chun Zeng , Xiu-yu Cai , Rong-ping Guo , Guang Nie , Ying Jin. Chromaticity and optical spectrum colorimetry of the tongue color in different syndromes of primary hepatic carcinoma. Journal of Chinese Integrative Medicine, 2012, 10(11): 1263-1271
[10] Oluwole Busayo Akinola. Should complementary and alternative medicine familiarisation modules be taught in African medical schools?. Journal of Chinese Integrative Medicine, 2011, 9(11): 1165-1169